Jessica Chutter

Jessica Chutter is the Vice Chair and Chair of Biotechnology Investment Banking at Morgan Stanley. During Chutter’s over 30-year career of building Morgan Stanley’s Biotechnology Franchise, she has been responsible for $75 billion of capital raising and $85 billion of strategic transactions. Chutter is focused on company-building, examples of which include raising $3 billion for Moderna, $2.4 billion for GW and $2.2 billion for BeiGene. During the pandemic Chutter led 15 IPOs totaling $3.1 billion, including those for Canadian-based Repare Therapeutics and Fusion Pharmaceuticals. Strategic transactions include advising Agios in its Oncology Business sale to Servier, Galapagos in its $5.1 billion transformative partnership with Gilead and Company sales of Clementia, Cubist, Pharmasset and Elan. She has also been involved in the creation of a new asset class involving royalty-backed debt (PhaRMA) where over $30 billion has been raised.

Chutter has a BA in Commerce/Honours Economics from McGill University and an MBA from Harvard Business School. Chutter is a director of Toronto Innovation Acceleration Partners and a member of the Board of Trustees of The Hospital for Sick Children (SickKids) and McGill’s Toronto Advisory Board. She resides in Toronto with her husband, Derek Berghuis, and has three children – Andrew, Jennifer and Kevin.

Chutter joined the Board of Trustees in 2020.